{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T22:45:50Z","timestamp":1778280350016,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.vaccine.2015.07.028","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T00:37:23Z","timestamp":1437525443000},"page":"4464-4471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-5167","authenticated-orcid":false,"given":"Gaston","family":"De Serres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta M.","family":"Skowronski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manale","family":"Ouakki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernand","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8023-3784","authenticated-orcid":false,"given":"Eveline","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3352-5749","authenticated-orcid":false,"given":"Monique","family":"Landry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Dupr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.07.028_bib0195","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","article-title":"Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis","volume":"381","author":"Salmon","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2015.07.028_bib0200","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/aje\/kws196","article-title":"Guillain-Barre syndrome during the 2009\u20132010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans","volume":"175","author":"Wise","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0205","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barre syndrome following influenza A (H1N1) 2009 monovalent vaccines","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2012.7342","article-title":"Risk of Guillain-Barre syndrome following H1N1 influenza vaccination in Quebec","volume":"308","author":"De Wals","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2015.07.028_bib0215","doi-asserted-by":"crossref","first-page":"e82222","DOI":"10.1371\/journal.pone.0082222","article-title":"Guillain-Barr\u00e9 syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe","volume":"9","author":"Romio","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0220","first-page":"S258","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines\u2014a multinational case control study in Europe","volume":"20","author":"Dieleman","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0225","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.1016\/j.vaccine.2011.08.069","article-title":"Guillain-Barre syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series","volume":"29","author":"Andrews","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.07.028_bib0230","doi-asserted-by":"crossref","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","article-title":"AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland","volume":"7","author":"Nohynek","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0235","doi-asserted-by":"crossref","first-page":"f794","DOI":"10.1136\/bmj.f794","article-title":"Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine: retrospective analysis","volume":"346","author":"Miller","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2015.07.028_bib0240","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/joim.12150","article-title":"Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up","volume":"275","author":"Persson","year":"2014","journal-title":"J Intern Med"},{"issue":"9","key":"10.1016\/j.vaccine.2015.07.028_bib0245","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.sleep.2013.03.020","article-title":"Storsaeter incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A","volume":"14","author":"Heier","year":"2013","journal-title":"J Sleep Med"},{"issue":"8","key":"10.1016\/j.vaccine.2015.07.028_bib0250","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.vaccine.2012.12.015","article-title":"The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns","volume":"31","author":"Wijnans","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2015.07.028_bib0255","doi-asserted-by":"crossref","first-page":"e108489","DOI":"10.1371\/journal.pone.0108489","article-title":"Risk of narcolepsy associated with inactivated adjuvanted (AS03) A\/H1N1 (2009) pandemic influenza vaccine in Quebec","volume":"9","author":"Montplaisir","year":"2014","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.vaccine.2015.07.028_bib0260","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/WNL.0000000000000987","article-title":"Vaccine Safety Datalink. Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States","volume":"83","author":"Duffy","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.vaccine.2015.07.028_bib0265","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1212\/WNL.0b013e3182020307","article-title":"Acute encephalomyelitis syndromes associated with H1N1 09 influenza vaccination","volume":"75","author":"Denholm","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0270","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1016\/j.vaccine.2011.08.093","article-title":"Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination","volume":"29","author":"Williams","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0275","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1590\/S0004-282X2011000400035","article-title":"Bithalamic compromise in acute disseminated encephalomyelitis following H1N1 influenza vaccine","volume":"69","author":"Fernandes","year":"2011","journal-title":"Arq Neuropsiatr"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0280","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3345\/kjp.2011.54.10.422","article-title":"An adverse event following 2009 H1N1 influenza vaccination: a case of acute disseminated encephalomyelitis","volume":"54","author":"Lee","year":"2011","journal-title":"Korean J Pediatr"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0285","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ejpn.2011.01.004","article-title":"Encephalitis after vaccination against H1N1 influenza virus","volume":"15","author":"Willi","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.07.028_bib0290","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/INF.0b013e3181f11126","article-title":"Adverse neurologic reactions after both doses of pandemic H1N1 influenza vaccine with optic neuritis and demyelination","volume":"30","author":"Lapphra","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"50","key":"10.1016\/j.vaccine.2015.07.028_bib0295","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1016\/j.vaccine.2013.10.033","article-title":"Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A\/H1N1 (H1N1pdm09) vaccine","volume":"31","author":"Rouleau","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2015.07.028_bib0300","first-page":"1309","article-title":"Pharmacovigilance study of influenza A H1N1 vaccination during the 2009-2010 season in France","volume":"195","author":"Montastruc","year":"2011","journal-title":"Bull Acad Natl Med"},{"issue":"6","key":"10.1016\/j.vaccine.2015.07.028_bib0305","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2515\/therapie\/2011075","article-title":"National campaign of vaccination against the flu A (H1N1)v: national follow-up of pharmacovigilance","volume":"66","author":"Durrieu","year":"2011","journal-title":"Therapie"},{"issue":"14","key":"10.1016\/j.vaccine.2015.07.028_bib0310","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1016\/j.vaccine.2011.01.056","article-title":"Adverse events following pandemic influenza vaccine Pandemrix\u00ae reported in the French military forces \u2013 2009\u20132010","volume":"29","author":"Mayet","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0315","doi-asserted-by":"crossref","first-page":"d5956","DOI":"10.1136\/bmj.d5956","article-title":"Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden","volume":"343","author":"Bardage","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0320","unstructured":"Government of Sweden. Final summary of adverse drug reaction reports in Sweden with Pandemrix through October 2009 \u2013 mid April 2010. June 2 2010 Available at: http:\/\/www.lakemedelsverket.se\/upload\/eng-mpa-se\/Pandemrix%20ADRs%20in%20Sweden%2015%20april%202010.pdf."},{"key":"10.1016\/j.vaccine.2015.07.028_bib0325","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1185\/030079906X115702","article-title":"Development and testing of a neuropathic pain screening questionnaire: ID Pain","volume":"22","author":"Portenoy","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.vaccine.2015.07.028_bib0330","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jpainsymman.2009.09.020","article-title":"Neuropathic pain in breast cancer survivors: using the ID pain as a screening tool","volume":"39","author":"Reyes-Gibby","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0335","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J Consult Clin Psychol"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0340","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"Validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0345","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0022-3956(90)90004-A","article-title":"The somatosensory amplification scale and its relationship to hypochondriasis","volume":"24","author":"Barsky","year":"1990","journal-title":"J Psychiatric Res"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0350","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1017\/S0033291700030026","article-title":"Attributions of common somatic symptoms","volume":"21","author":"Robbins","year":"1991","journal-title":"Psychol Med"},{"issue":"2","key":"10.1016\/j.vaccine.2015.07.028_bib0355","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jpsychores.2005.06.061","article-title":"Medically unexplained cutaneous sensory symptoms may represent somatoform dissociation: an empirical study","volume":"60","author":"Gupta","year":"2006","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0360","unstructured":"Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9. Bilan actualis\u00e9 de pharmacovigilance des vaccins antigrippaux A\/H1N1; May 2010. Available at: www.afssaps.fr\/. [accessed 02.08.11]."},{"key":"10.1016\/j.vaccine.2015.07.028_bib0365","series-title":"Twenty-second pandemic pharmacovigilance update","author":"European Medicines Agency (EMEA)","year":"2010"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0370","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1016\/j.vaccine.2010.09.021","article-title":"Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009 \u2013 January 31, 2010","volume":"28","author":"Vellozzi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.07.028_bib0375","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","article-title":"The reporting sensitivities of two passive surveillance systems for vaccine adverse events","volume":"85","author":"Rosenthal","year":"1995","journal-title":"Am J Pub Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1500972X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1500972X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T15:25:15Z","timestamp":1537457115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1500972X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":37,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0264410X1500972X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}